Key Takeaways
- MYCOPHYTO has finalized a €16 million Series A funding round.
- The round was led by Innovacom, BNP Paribas, and Bpifrance’s Deep Tech 2030 fund.
- New and existing investors include CDG Invest, Noshaq, RSI, and Crédit Agricole.
- The funding will support MYCOPHYTO’s first production facility and international expansion.
- MYCOPHYTO develops AI-formulated mycorrhizal biostimulants to improve crop resilience and soil health.
MYCOPHYTO Secures €16 Million Series A Funding Round
MYCOPHYTO has announced the completion of a €16 million Series A funding round to support its next phase of growth and accelerate its international ambitions. The round was led by Innovacom, BNP Paribas, and the Deep Tech 2030 fund managed by Bpifrance on behalf of the French State as part of the France 2030 initiative.
The financing also includes participation from CDG Invest and Noshaq, alongside renewed support from existing shareholders RSI and Crédit Agricole. According to the company, the Series A marks a major milestone in transitioning from early commercial traction to industrial-scale deployment.
Scaling Production and Expanding Internationally
With the new capital, MYCOPHYTO plans to significantly increase its production capacity through the construction of its first industrial facility. The future plant will integrate sustainable technologies and benefits from state-backed support following MYCOPHYTO’s selection under the France 2030 call for projects “Résilience et capacités agroalimentaires 2030.”
1 Comment